Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Gland Pharma Limited — Q3 FY26
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,695 crore, up 22% YoY, driven by broad-based growth across markets and a turnaround at Synexi.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,695 crore, up 22% YoY, driven by broad-based growth across markets and a turnaround at Synexi. Adjusted EBITDA grew 25% YoY to ₹449 crore, with margins at 26%. The US business grew 16% YoY, while Europe surged 54% YoY, partly due to Synexi's 39% topline growth. Synexi achieved €50 million revenue and positive EBITDA of €1.4 million, meeting guidance. Management guided for 12-13% organic growth in FY27 and 15% CAGR over 5 years, supported by new CDMO contracts, GLP-1/cartridge capacity expansion (40M to 140M units), and a ₹2,000 crore capex plan over 5 years. Key risk: potential delay in US approval for liraglutide, though European launches partially offset.
ग्लैंड फार्मा ने वित्त वर्ष 2026 की तीसरी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कुल कमाई ₹1,695 करोड़ रही, जो पिछले साल से 22% ज्यादा है। यह वृद्धि सभी बाजारों में बिक्री बढ़ने और सिनेक्सी कंपनी के सुधार से हुई। समायोजित EBITDA (कमाई में से कुछ खर्चे निकालने के बाद का मुनाफा) 25% बढ़कर ₹449 करोड़ हो गया, जो कमाई का 26% है। अमेरिका में बिक्री 16% और यूरोप में 54% बढ़ी। सिनेक्सी ने €50 करोड़ कमाई और €1.4 करोड़ मुनाफा कमाया। कंपनी अगले वित्त वर्ष में 12-13% और अगले 5 सालों में 15% सालाना वृद्धि का अनुमान लगाती है। इसके लिए वह नए कॉन्ट्रैक्ट, दवा बनाने की क्षमता बढ़ाने (4 करोड़ से 14 करोड़ यूनिट) और ₹2,000 करोड़ के निवेश की योजना बना रही है। जोखिम: अमेरिका में एक दवा (लिराग्लूटाइड) की मंजूरी में देरी हो सकती है, लेकिन यूरोप में बिक्री से इसकी भरपाई हो सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Liraglutide US approval delay
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Revenue Growth
₹8,290 million
+16% YoY
US revenue grew 16% YoY to ₹8,290 million in Q3, driven by volume growth of 19% and new GPO contracts.
Synexi Revenue
€50 million
+21% YoY
Synexi achieved €50 million revenue in Q3, the highest quarterly revenue in CY2025, with positive EBITDA of €1.4 million.
R&D Spend as % of Revenue
5.4%
+130bps YoY
R&D investment increased to 5.4% of revenue in Q3, up from 4.1% last year, focused on complex injectables.
Cartridge Fill-Finish Capacity
140 million units
+250%
Capacity expanding from 40M to 140M units; new line expected to be ready for exhibit batches by Q2 FY27.
What Changed vs Last Quarter
NEW
FY27 organic growth of 12-13%
Management expects base business to grow 12-13% in FY27, with potential upside from CDMO contracts and liraglutide US approval.
NEW
5-year organic CAGR of 15%
Company targets 15% organic CAGR over 5 years, excluding inorganic contributions, driven by capacity expansion and CDMO wins.
NEW
₹2,000 crore capex over 5 years
Planned capex of ~₹2,000 crore over next 5 years for brownfield expansions, BFS line, and CDMO contracts, with FY27 capex >₹400 crore.
NEW
Synexi annual revenue baseline of €200 million
Synexi's Q3 revenue of €50 million sets a baseline for annualized revenue of ~€200 million, with potential quarterly fluctuations.
DROPPED
FY26 consolidated revenue growth in mid-teens
Management reaffirmed mid-teens percentage revenue growth for FY26, driven by new launches and Senexi improvement.
DROPPED
Senexi EBITDA breakeven in Q3 FY26
Senexi is expected to achieve EBITDA breakeven in Q3 FY26, supported by €50M quarterly revenue target.
DROPPED
GLP-1 cartridge capacity expansion to 140M units
Cartridge fill-finish capacity to increase from 40M to 140M units by mid-FY27, targeting GLP-1 and insulin.
DROPPED
Biologic CDMO capacity expansion to 23k liters
Biologic CDMO capacity to expand from 8k to 23k liters in the next phase to support biosimilar and biologic fill-finish.
NEW RISK
Liraglutide US approval delay
Partner's US approval for liraglutide is delayed; additional data submitted in January 2026. If approval does not come through, revenue may be partially offset by European demand.
NEW RISK
Capacity constraints limiting growth
Existing lines are running at 80-90% utilization, with some at full capacity. New capacity additions are needed within 2 years to sustain growth.
NEW RISK
Synexi quarterly volatility
Despite turnaround, Synexi's revenue may fluctuate quarter-to-quarter due to product mix and customer ordering patterns.
NEW RISK
Pricing pressure in US generics
US pricing declined 5-6% YoY, offset by cost efficiencies. Sustained pricing erosion could pressure margins if cost savings are not maintained.
RISK GONE
Milestone revenue volatility
Milestone revenue was lower at ₹44-45 crore vs normal run rate of ₹75 crore, impacting overall revenue growth.
RISK GONE
Senexi turnaround execution
Senexi's planned shutdown and operational losses persist; breakeven in Q3 depends on achieving €50M quarterly revenue.
RISK GONE
Price erosion in US generics
While price erosion was flat this quarter, sustained competitive pricing could pressure margins in the base US business.
RISK GONE
GLP-1 capacity utilization ramp-up
New 100M cartridge capacity may take 2+ years to fully utilize, with revenue dependent on partner approvals and market access.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q2 FY26
Management reaffirmed mid-teens percentage revenue growth for FY26, driven by new launches and Senexi improvement.
Mentioned in Q1 FY26, Q2 FY26
New 100M cartridge capacity may take 2+ years to fully utilize, with revenue dependent on partner approvals and market access.
Mentioned in Q1 FY26, Q2 FY26
Cartridge fill-finish capacity to increase from 40M to 140M units by mid-FY27, targeting GLP-1 and insulin.
Fast read
Guidance and risk preview
Management expects base business to grow 12-13% in FY27, with potential upside from CDMO contracts and liraglutide US approval.
Partner's US approval for liraglutide is delayed; additional data submitted in January 2026.
View Risks →